Imperial Peptides UK has published educational guidance on handling, storage, and documentation of its lyophilised Ipamorelin 5mg, a peptide supplied strictly for Research Use Only. The guidance covers controlled storage conditions, batch traceability, Certificates of Analysis, and protection from…
Imperial Peptides UK has published educational guidance on the handling, storage, and documentation of its lyophilised Ipamorelin 5mg product, a peptide supplied strictly for Research Use Only RUO . The guidance consolidates best practice for laboratories working with the material, covering the lyophilised format, controlled storage conditions, batch-specific documentation, Certificates of Analysis, and the RUO designation that excludes any human or veterinary use.
The document arrives at a point where ipamorelin is appearing in sports medicine and doping control literature while its formal evidence base remains tiny. The Peptide Atlas registry holds no registered clinical trials for the molecule, and PubMed indexes six papers mentioning it. For a peptide in that position, between laboratory interest and clinical absence, the practical details of storage, documentation, and verification may determine whether any given experiment is trustworthy.
Below are the specifics of the guidance, the chemistry that explains why its warnings take the form they do, where ipamorelin sits in the indexed research base, and the questions the document leaves open.
The central fact of the guidance is the product itself: Ipamorelin 5mg, supplied in lyophilised form. Lyophilisation removes moisture from the peptide and helps support stability during storage and transport before laboratory research begins. One property of the material, its dryness, drives most of the handling advice that follows.
Researchers are told to minimise unnecessary exposure to moisture, excessive temperature changes, and repeated handling, and to maintain controlled laboratory conditions to preserve the integrity of the lyophilised material. The guidance groups the handling considerations into five items:
The environmental factors flagged for attention are temperature, moisture, light exposure, and unnecessary handling. Before beginning laboratory work, researchers should review the product label, the batch number, and the available analytical documentation. A Certificate of Analysis provides batch-specific information relating to identity, purity, and other analytical testing where applicable; it is the document that connects a physical vial to the supplier's quality record.
The guidance closes with a researcher checklist: confirm the Research Use Only status, verify the batch number, review the Certificate of Analysis, and minimise unnecessary handling. Imperial Peptides UK states that it supplies Ipamorelin 5mg strictly for Research Use Only, supported by product information, batch verification, and analytical transparency.
For a Research Use Only product there is no pharmacopoeia monograph and no regulatory release process. The Certificate of Analysis is therefore the only quality gate between the manufacturer's analytical laboratory and the end user's experiment. That is why the guidance treats it as part of the researcher checklist rather than as supplier paperwork. A batch number without a Certificate of Analysis is an unverifiable claim, and a Certificate of Analysis without a batch number cannot be traced to a physical vial. The two documents work as a pair, and the insistence on reviewing both before beginning work reflects that logic.
What the guidance is not: a clinical protocol, a stability study, or a quantitative specification. It does not state temperature or humidity set points, it does not list the analytical methods behind the Certificate of Analysis, and it does not declare a shelf life. It is a procedural document describing a research-quality storage and documentation workflow, and its utility and its limits both follow from that.
Ipamorelin is a synthetic peptide agonist at the growth hormone secretagogue receptor 1a GHSR-1a , the receptor for the endogenous hormone ghrelin. Signalling through this receptor stimulates growth hormone release, which is the pharmacology that underlies interest in the molecule for metabolic, cachexia, and performance applications. The indexed ferret study confirms the mechanism directly: ipamorelin, as a GHSR-1a agonist, inhibited cisplatin-induced weight loss in an animal model of chemotherapy-associated cachexia.
The reason the material must be protected, however, is chemistry rather than pharmacology. Peptide bonds are amide bonds, and amide bonds undergo hydrolysis. Water also drives deamidation of asparagine and glutamine side chains and raises molecular mobility within a solid, letting partially unfolded chains collide and aggregate. Oxidation, accelerated by light and trace metals, attacks methionine, cysteine, and aromatic residues. Every one of these pathways requires or is accelerated by water.
Lyophilisation removes that water. The peptide solution is frozen and dried under vacuum so that water sublimates directly from solid to vapour, leaving a porous, low-moisture cake. With water removed, molecular mobility is low and water-dependent degradation is slow. That is the basis for the claim that the lyophilised format supports stability during storage and transport.
But the dried cake is hygroscopic. It reabsorbs moisture from ambient air when a vial is opened, and it collects condensed water if a cold vial is warmed to room temperature before it has equilibrated. Every cycle of cold storage, warming, opening, and handling reintroduces some water and some degradation risk. That is why the guidance couples controlled storage with warnings against excessive temperature changes and repeated handling; the two warnings target the same failure mode from opposite ends.
Light protection is the same logic applied to photochemistry. Exposure to light sits on the guidance's list of environmental factors alongside temperature, moisture, and handling. For a research reagent, the cost of ignoring these factors is not a visible event. Degradation accumulates gradually, potency drifts, and assays that depend on the intact peptide produce results that are subtly wrong. In an experiment where the peptide is the independent variable, an undetected change in the material is an undetected change in the experiment.
The Peptide Atlas dataset for ipamorelin is small and sharply defined. It records 0 registered clinical trials on file and 6 indexed PubMed papers. One third-party laboratory purity test is on file, with a highest observed purity of 99.927%. The Peptide Atlas reference page for the compound https://peptideatlas.co/peptides/ipamorelin collates the registry and literature data.
Two of the six papers are primary pharmacology studies. The 2024 study in Physiology & Behavior examined the GHSR-1a agonists anamorelin and ipamorelin and reported that both inhibit cisplatin-induced weight loss in ferrets, with anamorelin also exhibiting anti-emetic effects via a central mechanism PMID 39043357, 2024-10-01 . This is the clearest indexed experimental evidence of ipamorelin's mechanism and of a plausible therapeutic direction: preserving body weight in catabolic states. The other primary study, in Animal Reproduction Science, used the ghrelin agonist ipamorelin acetate to probe the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus PMID 38996787, 2024-09-01 . That the same receptor agonist is pharmacologically active in a ferret and in a teleost fish points to deep evolutionary conservation of the ghrelin axis, and to a research use of ipamorelin as a tool compound.
The other three indexed papers are reviews and primers directed at physicians:
The resulting picture is asymmetric. A molecule with two primary papers and no clinical trials is prominent enough to anchor a doping-review narrative in sports medicine, common enough to appear in orthopaedic physician primers, and active enough in a mammalian cachexia model to be grouped with anamorelin. The single third-party purity result of 99.927% shows what reagent-grade ipamorelin can look like when a batch is actually tested. But one result is one data point, and the gap between the molecule's visibility outside clinical research and the thinness of its formal evidence base is the defining feature of the literature.
Evidence quality matters as much as volume when reading this literature. The three physician-facing papers are reviews and primers: expert commentary that documents a clinical encounter with peptide use, not data on efficacy or safety. The doping review's title poses a question about a new era of peptide use in sport and bodybuilding, and its publication in a sports medicine journal indicates that the phenomenon has reached the clinic's doorstep, but a review does not establish whether ipamorelin is effective or safe in humans. A primer can tell a physician what a patient is likely holding in a vial; it cannot tell them what the contents do at clinically relevant doses. Only the two primary studies carry experimental weight, and both are preclinical.
For researchers, the guidance converts handling best practice into verifiable steps. Confirming the RUO status, verifying the batch number, reviewing the Certificate of Analysis, and minimising unnecessary handling are process controls, and in peptide research the Certificate of Analysis is the primary quality artefact tying a physical vial to a supplier's analytical record. Reviewing it before beginning work means identity and purity claims are checked at receipt, not after an experiment has failed or produced unreproducible data.
The reproducibility argument runs through the document. A lyophilised cake that has absorbed moisture, seen light, or been cycled through temperature changes is not the same material it was at release. If that change is silent, the experiment is silently compromised. The batch number and the Certificate of Analysis give the researcher a baseline; controlled storage protects that baseline; and the documentation allows results to be traced to a defined material. For laboratories that publish peptide studies, that chain of custody is part of what makes their results interpretable by others.
Documentation discipline extends into the laboratory notebook. If the batch number and the Certificate of Analysis reference are recorded at the point of receipt, then every experiment performed with that vial can be traced back to a defined analytical record. That practice is cheap, but it is what turns a peptide experiment from an anecdote into a reproducible data point. Publications that identify the supplier, the batch, and the purity assessment allow other laboratories to repeat the work with comparable or deliberately different material, which is the normal way a field learns whether a result depends on the molecule or on the particular vial.
For the supply chain, the guidance documents an intended model of reagent supply: a defined quantity of 5mg, a defined lyophilised format, batch traceability, an analytical…
Peptides referenced: Ipamorelin, Growth Hormone, Anamorelin, Ghrelin.
Vendors referenced: Imperial Peptides.
Related reading: How Ipamorelin Is Researched in Controlled Laboratory Settings, Ipamorelin Stability: What Researchers Should Know, New Online Platform Offers High-Purity Research Peptides, Peptides: Beyond Weight Loss, Promise Unsettled.